Mapping the IMiD-dependent cereblon interactome using BioID-proximity labelling
- Author(s)
- Costacurta, M; Sandow, JJ; Maher, B; Susanto, O; Vervoort, SJ; Devlin, JR; Garama, D; Condina, MR; Steele, JR; Kahrood, HV; Gough, D; Johnstone, RW; Shortt, J;
- Journal Title
- FEBS Journal
- Publication Type
- Online publication before print
- Abstract
- Immunomodulatory imide drugs (IMiDs) are central components of therapy for multiple myeloma (MM). IMiDs bind cereblon (CRBN), an adaptor for the CUL4-DDB1-RBX1 E3 ligase to change its substrate specificity and induce degradation of 'neosubstrate' transcription factors that are essential to MM cells. Mechanistic studies to date have largely focussed on mediators of therapeutic activity and insight into clinical IMiD toxicities is less developed. We adopted BioID2-dependent proximity labelling (BioID2-CRBN) to characterise the CRBN interactome in the presence and absence of various IMiDs and the proteasome inhibitor, bortezomib. We aimed to leverage this technology to further map CRBN interactions beyond what has been achieved by conventional proteomic techniques. In support of this approach, analysis of cells expressing BioID2-CRBN following IMiD treatment displayed biotinylation of known CRBN interactors and neosubstrates. We observed that bortezomib alone significantly modifies the CRBN interactome. Proximity labelling also suggested that IMiDs augment the interaction between CRBN and proteins that are not degraded, thus designating 'neointeractors' distinct from previously disclosed 'neosubstrates'. Here we identify Non-Muscle Myosin Heavy Chain IIA (MYH9) as a putative CRBN neointeractor that may contribute to the haematological toxicity of IMiDs. These studies provide proof of concept for proximity labelling technologies in the mechanistic profiling of IMiDs and related E3-ligase-modulating drugs.
- Publisher
- Wiley
- Keywords
- BioID2; IMiDs; bortezomib; cereblon; myosin
- Department(s)
- Laboratory Research
- Publisher's Version
- https://doi.org/10.1111/febs.17196
- Open Access at Publisher's Site
https://doi.org/10.1111/febs.17196- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-07-30 06:26:22
Last Modified: 2024-07-30 06:34:07